FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297149746> ?p ?o ?g. }

• W4297149746 endingPage "4651" @default.
• W4297149746 startingPage "4651" @default.
• W4297149746 abstract "Hepatocellular carcinoma (HCC) is characterized by poor survival rate and quality of life, while available treatments remain generally limited. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) originally emerged as drugs for the management of diabetes, but have also been shown to alleviate cardiorenal risk. Furthermore, they have demonstrated a wide range of extraglycemic effects that led to their evaluation as potential therapies for a variety of diseases beyond diabetes, such as obesity, neurogenerative disorders and nonalcoholic fatty liver disease. Given the presence of the GLP-1 receptor in hepatocytes, animal data suggest that GLP-1 RAs could regulate molecular pathways that are deeply involved in the genesis and progression of HCC, including inflammatory responses, tumor cell proliferation and oxidative stress, through direct and indirect effects on liver cells. However, future studies must assess several aspects of the benefit-to-risk ratio of the use of GLP-1 RAs in patients with HCC, including co-administration with approved systemic therapies, the incidence of gastrointestinal side effects in a high-risk population, and weight loss management in individuals with poor nutritional status and high rates of cancer cachexia. In this narrative review, we discuss the potential role of GLP-1 analogs in the treatment of HCC, focusing on the molecular mechanisms that could justify a possible benefit, but also referring to the potential clinical implications and areas for future research." @default.
• W4297149746 created "2022-09-27" @default.
• W4297149746 creator A5056619172 @default.
• W4297149746 creator A5064623738 @default.
• W4297149746 creator A5086736907 @default.
• W4297149746 creator A5087679429 @default.
• W4297149746 date "2022-09-24" @default.
• W4297149746 modified "2023-10-15" @default.
• W4297149746 title "How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma" @default.
• W4297149746 cites W1485586005 @default.
• W4297149746 cites W1942040918 @default.
• W4297149746 cites W1968002849 @default.
• W4297149746 cites W1991953785 @default.
• W4297149746 cites W1995762768 @default.
• W4297149746 cites W1996164453 @default.
• W4297149746 cites W2004409542 @default.
• W4297149746 cites W2009155872 @default.
• W4297149746 cites W2041551639 @default.
• W4297149746 cites W2054649558 @default.
• W4297149746 cites W2075514437 @default.
• W4297149746 cites W2084948079 @default.
• W4297149746 cites W2092833954 @default.
• W4297149746 cites W2106036385 @default.
• W4297149746 cites W2111951337 @default.
• W4297149746 cites W2113983413 @default.
• W4297149746 cites W2132078039 @default.
• W4297149746 cites W2134141467 @default.
• W4297149746 cites W2135205634 @default.
• W4297149746 cites W2136579005 @default.
• W4297149746 cites W2141229551 @default.
• W4297149746 cites W2143756124 @default.
• W4297149746 cites W2151567146 @default.
• W4297149746 cites W2163892210 @default.
• W4297149746 cites W2169274492 @default.
• W4297149746 cites W2215535790 @default.
• W4297149746 cites W2550011910 @default.
• W4297149746 cites W2551488436 @default.
• W4297149746 cites W2559954620 @default.
• W4297149746 cites W2567512854 @default.
• W4297149746 cites W2568210207 @default.
• W4297149746 cites W2603043036 @default.
• W4297149746 cites W2613259257 @default.
• W4297149746 cites W2629223022 @default.
• W4297149746 cites W2735960098 @default.
• W4297149746 cites W2759997926 @default.
• W4297149746 cites W2763187217 @default.
• W4297149746 cites W2808062019 @default.
• W4297149746 cites W2811426001 @default.
• W4297149746 cites W2891117167 @default.
• W4297149746 cites W2913950552 @default.
• W4297149746 cites W2941033601 @default.
• W4297149746 cites W2946574770 @default.
• W4297149746 cites W2948622224 @default.
• W4297149746 cites W2955615964 @default.
• W4297149746 cites W2968073288 @default.
• W4297149746 cites W2969637142 @default.
• W4297149746 cites W2979288514 @default.
• W4297149746 cites W2980881483 @default.
• W4297149746 cites W2981702768 @default.
• W4297149746 cites W2987247827 @default.
• W4297149746 cites W2998955205 @default.
• W4297149746 cites W3002712905 @default.
• W4297149746 cites W3004644667 @default.
• W4297149746 cites W3006785779 @default.
• W4297149746 cites W3007686565 @default.
• W4297149746 cites W3015945042 @default.
• W4297149746 cites W3025256756 @default.
• W4297149746 cites W3034691659 @default.
• W4297149746 cites W3047956076 @default.
• W4297149746 cites W3084829832 @default.
• W4297149746 cites W3088101729 @default.
• W4297149746 cites W3097287185 @default.
• W4297149746 cites W3108138500 @default.
• W4297149746 cites W3109302943 @default.
• W4297149746 cites W3125674226 @default.
• W4297149746 cites W3126030429 @default.
• W4297149746 cites W3133470123 @default.
• W4297149746 cites W3134100899 @default.
• W4297149746 cites W3138484572 @default.
• W4297149746 cites W3138492147 @default.
• W4297149746 cites W3139281949 @default.
• W4297149746 cites W3165816309 @default.
• W4297149746 cites W3177122952 @default.
• W4297149746 cites W3178974444 @default.
• W4297149746 cites W3190321126 @default.
• W4297149746 cites W3193656600 @default.
• W4297149746 cites W3194466821 @default.
• W4297149746 cites W3200446817 @default.
• W4297149746 cites W3208498374 @default.
• W4297149746 cites W3209709155 @default.
• W4297149746 cites W3211702740 @default.
• W4297149746 cites W3213283278 @default.
• W4297149746 cites W4200020111 @default.
• W4297149746 cites W4200253504 @default.
• W4297149746 cites W4200439235 @default.
• W4297149746 cites W4210880022 @default.
• W4297149746 cites W4220859757 @default.
• W4297149746 cites W4221056231 @default.

• next